Companies › Beijing Immunochina Medical Science & Technology
2 active drug programs in 23 registered trials: 14 Phase 2, 9 Phase 1; Oncology, Neurology, Hematology; next expected readout Jun 2035.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Fludarabine Phosphate (IM19) Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor | RRM1, RRM2B, RRM2, POLA1, POLD4 | Phase 1 | NHL; B-cell Acute Lymphoblastic Leukemia; Myelodysplastic Syndromes; Refractory Idiopathic Aplastic Anemia … | Jun 2035 |
| IM96 CAR-T Cells CAR-T cell therapy targeting unknown antigen | – | Phase 1 | Colorectal Cancer (CRC) | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03509961 | Fludarabine Phosphate (IM19) | Phase 2 | B-cell Acute Lymphoblastic Leukemia | Oncology | Jul 2025 |
| NCT06718738 | IM96 CAR-T Cells | Phase 1 | Colorectal Cancer (CRC) | Oncology | Aug 2025 |
| NCT05832515 | Fludarabine Phosphate (IM19) | Phase 1 | Multiple Sclerosis | Neurology | Dec 2026 |
| NCT00544466 | Fludarabine Phosphate (IM19) | Phase 1 | Leukemia | Oncology | Dec 2026 |
| NCT00920972 | Fludarabine Phosphate (IM19) | Phase 1 | Metabolic Disorders | Oncology | Dec 2026 |
| NCT06098326 | Fludarabine Phosphate (IM19) | Phase 2 | Myelodysplastic Syndromes | Hematology | Dec 2026 |
| NCT05126849 | Fludarabine Phosphate (IM19) | Phase 2 | Refractory Idiopathic Aplastic Anemia | Hematology | Jan 2027 |
| NCT06834529 | Fludarabine Phosphate (IM19) | Phase 1 | Relapsed or Refractory B Cell Leukemia and Lymphoma | Oncology | Jan 2027 |
| NCT04262843 | Fludarabine Phosphate (IM19) | Phase 2 | Acute Lymphoblastic Leukemia | Oncology | May 2027 |
| NCT03192397 | Fludarabine Phosphate (IM19) | Phase 1 | Acute Myeloid Leukemia in Remission | Oncology | May 2027 |
| NCT07232953 | Fludarabine Phosphate (IM19) | Phase 2 | Acute Myeloid Leukaemia (AML) | Oncology | Jun 2027 |
| NCT07232953 | Fludarabine Phosphate (IM19) | Phase 2 | Acute Myeloid Leukaemia (AML) | Oncology | Jun 2027 |
| NCT02250937 | Fludarabine Phosphate (IM19) | Phase 2 | Acute Myeloid Leukemia | Oncology | Oct 2027 |
| NCT07410494 | Fludarabine Phosphate (IM19) | Phase 1 | Cancer | Oncology | Dec 2027 |
| NCT07410494 | Fludarabine Phosphate (IM19) | Phase 1 | Cancer | Oncology | Dec 2027 |
| NCT02629809 | Fludarabine Phosphate (IM19) | Phase 2 | Chronic Lymphocytic Leukemia | Oncology | Mar 2028 |
| NCT06869265 | Fludarabine Phosphate (IM19) | Phase 2 | Acute Myeloid Leukemia (AML) | Oncology | Apr 2028 |
| NCT03980769 | Fludarabine Phosphate (IM19) | Phase 2 | Non-Neoplastic Hematopoietic and Lymphoid Cell Disorder | Oncology | Jul 2028 |
| NCT02861417 | Fludarabine Phosphate (IM19) | Phase 2 | Hematopoietic and Lymphoid Cell Neoplasm | Oncology | Aug 2028 |
| NCT00801489 | Fludarabine Phosphate (IM19) | Phase 2 | Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 | Hematology | Oct 2028 |
| NCT06013423 | Fludarabine Phosphate (IM19) | Phase 2 | Acute Leukemia of Ambiguous Lineage | Oncology | Oct 2031 |
| NCT07582172 | Fludarabine Phosphate (IM19) | Phase 2 | Acute Myeloid Leukemia With Complex Karyotype | Oncology | Nov 2031 |
| NCT04440436 | Fludarabine Phosphate (IM19) | Phase 1 | NHL | Oncology | Jun 2035 |
Jiangsu Healthy Life Innovation Medical Technology Theravia InnoPharmax Jiangsu Hansoh Pharmaceutical Gilead Sciences
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.